These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18300698)

  • 1. Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis.
    Bourgeois N; Lachaud L; Reynes J; Rouanet I; Mahamat A; Bastien P
    J Acquir Immune Defic Syndr; 2008 May; 48(1):13-9. PubMed ID: 18300698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring prognosis in chronic relapsing visceral leishmaniasis among HIV-infected patients: Circulating Leishmania DNA.
    Cota GF; de Sousa MR; de Assis TSM; Pinto BF; Rabello A
    Acta Trop; 2017 Aug; 172():186-191. PubMed ID: 28501450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.
    ter Horst R; Collin SM; Ritmeijer K; Bogale A; Davidson RN
    Clin Infect Dis; 2008 Jun; 46(11):1702-9. PubMed ID: 18419422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.
    López-Vélez R
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():143-7. PubMed ID: 14678641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.
    Cota GF; de Sousa MR; Rabello A
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1153. PubMed ID: 21666786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
    Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study.
    Abongomera C; Diro E; Vogt F; Tsoumanis A; Mekonnen Z; Admassu H; Colebunders R; Mohammed R; Ritmeijer K; van Griensven J
    Clin Infect Dis; 2017 Oct; 65(10):1703-1710. PubMed ID: 29020196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic High-Level Parasitemia in HIV-Infected Individuals With or Without Visceral Leishmaniasis in an Endemic Area in Northwest Ethiopia: Potential Superspreaders?
    van Griensven J; van Henten S; Kibret A; Kassa M; Beyene H; Abdellati S; de Hondt A; Adriaensen W; Vogt F; Pareyn M; Ritmeijer K; Diro E
    Clin Infect Dis; 2024 Jul; 79(1):240-246. PubMed ID: 38193647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; Colebunders R; van Loen H; Menten J; Lynen L; Hailu A; van Griensven J
    PLoS Negl Trop Dis; 2015; 9(10):e0004087. PubMed ID: 26431253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New world Leishmania spp. infection in people living with HIV: Concerns about relapses and secondary prophylaxis.
    Araújo CF; Oliveira IBN; Silva MVT; Pereira LIA; Pinto SA; Silveira MB; Dorta ML; Fonseca SG; Gomes RS; Ribeiro-Dias F
    Acta Trop; 2021 Dec; 224():106146. PubMed ID: 34562423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; van Loen H; Tsoumanis A; Adriaensen W; Hailu A; Griensven JV
    Clin Infect Dis; 2018 Jan; 66(3):444-451. PubMed ID: 29020217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoproliferative response after stimulation with soluble leishmania antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ patients.
    Castro A; Carrillo E; San Martín JV; Botana L; Molina L; Matía B; Fernandez L; Horrillo L; Ibarra-Meneses A; Sanchez C; Ruiz-Giardin JM; Moreno J
    Acta Trop; 2016 Dec; 164():345-351. PubMed ID: 27693332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.
    Pintado V; Martín-Rabadán P; Rivera ML; Moreno S; Bouza E
    Medicine (Baltimore); 2001 Jan; 80(1):54-73. PubMed ID: 11204503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.
    Sinha PK; van Griensven J; Pandey K; Kumar N; Verma N; Mahajan R; Kumar P; Kumar R; Das P; Mitra G; Flevaud L; Ferreyra C; Remartinez D; Pece M; Palma PP
    Clin Infect Dis; 2011 Oct; 53(7):e91-8. PubMed ID: 21890763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.
    Lopez-Velez R; Perez-Molina JA; Guerrero A; Baquero F; Villarrubia J; Escribano L; Bellas C; Perez-Corral F; Alvar J
    Am J Trop Med Hyg; 1998 Apr; 58(4):436-43. PubMed ID: 9574788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral Leishmaniasis, with special reference to AIDS patients.
    Lachaud L; Dereure J; Chabbert E; Reynes J; Mauboussin JM; Oziol E; Dedet JP; Bastien P
    J Clin Microbiol; 2000 Jan; 38(1):236-40. PubMed ID: 10618093
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    van Griensven J; Mengesha B; Mekonnen T; Fikre H; Takele Y; Adem E; Mohammed R; Ritmeijer K; Vogt F; Adriaensen W; Diro E
    Front Cell Infect Microbiol; 2018; 8():94. PubMed ID: 29651411
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I; Falcó V; Crespo M; Riera C; Ribera E; Curran A; Carrio J; Diaz M; Villar del Saz S; Fisa R; López-Chejade P; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Oct; 60(4):837-42. PubMed ID: 17684055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature.
    Antinori S; Calattini S; Longhi E; Bestetti G; Piolini R; Magni C; Orlando G; Gramiccia M; Acquaviva V; Foschi A; Corvasce S; Colomba C; Titone L; Parravicini C; Cascio A; Corbellino M
    Clin Infect Dis; 2007 Jun; 44(12):1602-10. PubMed ID: 17516404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.